Details of the Drug

General Information of Drug (ID: DM6CLBN)

Drug Name
Danaparoid
Synonyms Orgaran (TN)
Indication
Disease Entry ICD 11 Status REF
Deep venous clot BD71 Approved [1], [2]
Therapeutic Class
Anticoagulants
ADMET Property
Bioavailability
The bioavailability of drug is 60% [3]
Clearance
The total plasma clearance of drug is 0.36 L/h [4]
Elimination
Renal excretion is the main route of elimination, accounting for approximately 40-50% of the total clearance of antifactor Xa activity following intravenous administration of danaparoid [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 19.2 - 24.5 hours [4]
Metabolism
The drug is metabolized via the hepatic [4]
Vd
The volume of distribution (Vd) of drug is 9.1 L [4]
Cross-matching ID
DrugBank ID
DB06754
TTD ID
D0P3SY

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor Xa (F10) TTCIHJA FA10_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Deep venous clot
ICD Disease Classification BD71
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Coagulation factor Xa (F10) DTT F10 4.84E-02 -0.28 -0.9
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Danaparoid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Danaparoid and Levomilnacipran. Chronic pain [MG30] [15]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Danaparoid and Regorafenib. Colorectal cancer [2B91] [16]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Danaparoid and Ardeparin. Coronary thrombosis [BA43] [17]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Danaparoid and Vortioxetine. Depression [6A70-6A7Z] [15]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Danaparoid and Apigenin. Discovery agent [N.A.] [18]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Danaparoid and Avapritinib. Gastrointestinal stromal tumour [2B5B] [16]
Aliskiren DM1BV7W Moderate Increased risk of hyperkalemia by the combination of Danaparoid and Aliskiren. Hypertension [BA00-BA04] [19]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Danaparoid and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [20]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Danaparoid and Acalabrutinib. Mature B-cell lymphoma [2A85] [21]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Danaparoid and Ibrutinib. Mature B-cell lymphoma [2A85] [22]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Danaparoid and Ponatinib. Mature B-cell lymphoma [2A85] [23]
Fedratinib DM4ZBK6 Major Increased risk of bleeding by the combination of Danaparoid and Fedratinib. Myeloproliferative neoplasm [2A20] [24]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Danaparoid and Ruxolitinib. Myeloproliferative neoplasm [2A20] [17]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Danaparoid and Vorapaxar. Myocardial infarction [BA41-BA43] [17]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Danaparoid and Nepafenac. Osteoarthritis [FA00-FA05] [25]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Danaparoid and MK-4827. Ovarian cancer [2C73] [16]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Danaparoid and Choline salicylate. Postoperative inflammation [1A00-CA43] [26]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Danaparoid and Curcumin. Solid tumour/cancer [2A00-2F9Z] [27]
Brilinta DMBR01X Major Increased risk of bleeding by the combination of Danaparoid and Brilinta. Thrombosis [DB61-GB90] [17]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Danaparoid and Cabozantinib. Thyroid cancer [2D10] [28]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Danaparoid and Betrixaban. Venous thromboembolism [BD72] [24]
⏷ Show the Full List of 21 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6804).
2 A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001 Jun;85(6):950-7.
3 Somogyi A, Gugler R: Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet. 1983 Nov-Dec;8(6):463-95. doi: 10.2165/00003088-198308060-00001.
4 Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs. 1997 Dec;54(6):903-24.
5 Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
6 Pfizer. Product Development Pipeline. March 31 2009.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
9 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
10 Company report (Portola)
11 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
12 Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
13 Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
14 Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
15 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
18 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
19 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
20 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
21 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
22 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
23 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
24 Product Information. Fragmin (dalteparin). Pharmacia and Upjohn, Kalamazoo, MI.
25 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
26 Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8. [PMID: 5490567]
27 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
28 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.